The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.

A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...

A shortage of Danish drugmaker Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...

Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...

Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's ...